InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,221.42
(
-0.02%
)
US TECH 100
17,726.80
(
0.25%
)
Dow Jones
39,431.51
(
-0.21%
)
Brent Oil
83.24
(
1.04%
)
Bitcoin
63,137.22
(
2.75%
)
Post# of 3898
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

l2errtx

Send PM Follow Ignore
Followers 1
Posts 3
Boards Moderated 0
Alias Born 05/14/2018

l2errtx

Re: None

Wednesday, 05/16/2018 10:29:54 AM

Wednesday, May 16, 2018 10:29:54 AM

Post# of 3898
Rexahn Phase 2a Combination Study of RX-3117 and Abraxane® in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage

https://seekingalpha.com/pr/17163439-rexahn-phase-2a-combination-study-rxminus-3117-abraxane-first-line-metastatic-pancreatic
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
InvestorsHub NewsWire

Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM

VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM

Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM

Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM

Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM

Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM

Start posting your company's news
Only $200 per official company press release!